Story perspectives

Health Canada Approves First Alzheimer's Drug, Lecanemab

10/27/2025

48 5

Summary

Story summary

Health Canada granted conditional authorization for lecanemab, the first disease-modifying Alzheimer's drug, for mild cognitive impairment or early-stage dementia.
The approval followed a review lasting over two years since Eisai Co., Ltd.'s application.
Lecanemab is administered by intravenous infusion and targets beta-amyloid proteins.
It can slow progression but does not halt Alzheimer's and carries risks of severe side effects for some genetic markers.

1 of 1

Story summary

Health Canada granted conditional authorization for lecanemab, the first disease-modifying Alzheimer's drug, for mild cognitive impairment or early-stage dementia.
The approval followed a review lasting over two years since Eisai Co., Ltd.'s application.
Lecanemab is administered by intravenous infusion and targets beta-amyloid proteins.
It can slow progression but does not halt Alzheimer's and carries risks of severe side effects for some genetic markers.